You are here

Phase 3 Trial of Odanacatib for Osteoporosis Is Halted Early After Drug Meets Efficacy Endpoints

The randomized, placebo-controlled trial was designed to evaluate the efficacy and safety of odanacatib in reducing the risk of fracture in more than 1,600 postmenopausal women with osteoporosis. The trial started in 2007 and was expected to continue until hip fractures were reported in a total of 237 women. The interim analysis was conducted by the DMC as planned when 70% of the targeted number of hip fractures had been reported.

Final results of the study will be submitted for presentation and publication in 2013.

Odanacatib selectively inhibits cathepsin K, the primary enzyme in osteoclasts that digest proteins during bone resorption. This mechanism of action allows odanacatib to improve the balance between bone resorption and bone formation in osteopororsis.

For more information, visit the Reuters Web site.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug